Literature DB >> 15598764

Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites.

Alice S Whittemore1, Gail Gong, Esther M John, Valerie McGuire, Frederick P Li, Kimberly L Ostrow, Richard Dicioccio, Anna Felberg, Dee W West.   

Abstract

Data from several countries indicate that 1% to 2% of Ashkenazi Jews carry a pathogenic ancestral mutation of the tumor suppressor gene BRCA1. However, the prevalence of BRCA1 mutations among non-Ashkenazi Whites is uncertain. We estimated mutation carrier prevalence in U.S. non-Hispanic Whites, specific for Ashkenazi status, using data from two population-based series of San Francisco Bay Area patients with invasive cancers of the breast or ovary, and data on breast and ovarian cancer risks in Ashkenazi and non-Ashkenazi carriers. Assuming that 90% of the BRCA1 mutations were detected, we estimate a carrier prevalence of 0.24% (95% confidence interval, 0.15-0.39%) in non-Ashkenazi Whites, and 1.2% (95% confidence interval, 0.5-2.6%) in Ashkenazim. When combined with U.S. White census counts, these prevalence estimates suggest that approximately 550,513 U.S. Whites (506,206 non-Ashkenazim and 44,307 Ashkenazim) carry germ line BRCA1 mutations. These estimates may be useful in guiding resource allocation for genetic testing and genetic counseling and in planning preventive interventions.

Entities:  

Mesh:

Year:  2004        PMID: 15598764

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  44 in total

Review 1.  Population genetic testing for cancer susceptibility: founder mutations to genomes.

Authors:  William D Foulkes; Bartha Maria Knoppers; Clare Turnbull
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

Review 2.  Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Authors:  David J Hughes
Journal:  Fam Cancer       Date:  2008-02-19       Impact factor: 2.375

3.  Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer.

Authors:  Reshma Jagsi; Kent A Griffith; Allison W Kurian; Monica Morrow; Ann S Hamilton; John J Graff; Steven J Katz; Sarah T Hawley
Journal:  J Clin Oncol       Date:  2015-04-06       Impact factor: 44.544

4.  The latent class twin method.

Authors:  Stuart G Baker
Journal:  Biometrics       Date:  2016-01-11       Impact factor: 2.571

5.  Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.

Authors:  Kathleen E Malone; Colin B Begg; Robert W Haile; Ake Borg; Patrick Concannon; Lina Tellhed; Shanyan Xue; Sharon Teraoka; Leslie Bernstein; Marinela Capanu; Anne S Reiner; Elyn R Riedel; Duncan C Thomas; Lene Mellemkjaer; Charles F Lynch; John D Boice; Hoda Anton-Culver; Jonine L Bernstein
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

6.  Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations.

Authors:  Daniel H Kim; Beth Crawford; John Ziegler; Mary S Beattie
Journal:  Fam Cancer       Date:  2008-10-15       Impact factor: 2.375

7.  BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research.

Authors:  Susan L Neuhausen; Hilmi Ozcelik; Melissa C Southey; Esther M John; Andrew K Godwin; Wendy Chung; Jeniffer Iriondo-Perez; Alexander Miron; Regina M Santella; Alice Whittemore; Irene L Andrulis; Saundra S Buys; Mary B Daly; John L Hopper; Daniela Seminara; Ruby T Senie; Mary Beth Terry
Journal:  Breast Cancer Res Treat       Date:  2008-08-14       Impact factor: 4.872

8.  Assessment of Background Parenchymal Enhancement and Lesion Kinetics in Breast MRI of BRCA 1/2 Mutation Carriers Compared to Matched Controls Using Quantitative Kinetic Analysis.

Authors:  Alana A Lewin; Sungheon Gene Kim; James S Babb; Amy N Melsaether; Jason McKellop; Melanie Moccaldi; Ana Paula Klautau Leite; Linda Moy
Journal:  Acad Radiol       Date:  2016-01-07       Impact factor: 3.173

9.  Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing.

Authors:  Anna P Sokolenko; Dmitry A Voskresenskiy; Aglaya G Iyevleva; Elena M Bit-Sava; Nadezhda I Gutkina; Maxim S Anisimenko; Nathalia Yu Sherina; Nathalia V Mitiushkina; Yulia M Ulibina; Olga S Yatsuk; Olga A Zaitseva; Evgeny N Suspitsin; Alexandr V Togo; Valery A Pospelov; Sergey P Kovalenko; Vladimir F Semiglazov; Evgeny N Imyanitov
Journal:  Hered Cancer Clin Pract       Date:  2009-01-26       Impact factor: 2.857

10.  The ordering of expression among a few genes can provide simple cancer biomarkers and signal BRCA1 mutations.

Authors:  Xue Lin; Bahman Afsari; Luigi Marchionni; Leslie Cope; Giovanni Parmigiani; Daniel Naiman; Donald Geman
Journal:  BMC Bioinformatics       Date:  2009-08-20       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.